The behavioral pharmacology of NMDA receptor antagonists
There is considerable interest in the development of NMDA antagonists as potential therapeutic agents in the treatment of convulsant, neurodegenerative and anxiety disorders. Because the clinical use of phencyclidine (PCP) has been precluded by its psychotomimetic effects and abuse potential, there...
Gespeichert in:
| Veröffentlicht in: | Trends in pharmacological sciences (Regular ed.) 1990-10, Vol.11 (10), p.423-428 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 428 |
|---|---|
| container_issue | 10 |
| container_start_page | 423 |
| container_title | Trends in pharmacological sciences (Regular ed.) |
| container_volume | 11 |
| creator | Willetts, Joyce Balster, Robert L. Leander, J.David |
| description | There is considerable interest in the development of NMDA antagonists as potential therapeutic agents in the treatment of convulsant, neurodegenerative and anxiety disorders. Because the clinical use of phencyclidine (PCP) has been precluded by its psychotomimetic effects and abuse potential, there has been concern that other NMDA antagonists including those acting competitively might produce similar untoward effects. However, the studies in animals, reviewed here by Joyce Willetts, Robert Balster and David Leander,
suggest that while there are certain similarities in the behavioral effects of PCP-like and competitive antagonists, there are also differences. These differences have implications for the development of NMDA antagonists with less likelihood for producing PCP-like side-effects. |
| doi_str_mv | 10.1016/0165-6147(90)90150-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80163510</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0165614790901507</els_id><sourcerecordid>80163510</sourcerecordid><originalsourceid>FETCH-LOGICAL-c448t-b5d3a1c86826676ecf1e8d11722804283df6e2b5eaaab4bf1d2e4cff13e0fa13</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EKqXwByBlhWAR8COJnQ1SVZ5SgU33luOMW6MkDnZaqX-PSyuWLEYjzdx7R3MQuiT4jmBS3MfK04Jk_KbEtyUmOU75ERoTwVnKOMuP0fhPcorOQvjCGDNGyQiNaJzxMhsjsVhBUsFKbazzqkn6lfKt0q5xy23iTPLx_jhNPGjoB-cT1Q1q6TobhnCOToxqAlwc-gQtnp8Ws9d0_vnyNpvOU51lYkirvGaKaFEIWhS8AG0IiJoQTqnAGRWsNgXQKgelVJVVhtQUMm0MYYCNImyCrvexvXffawiDbG3Q0DSqA7cOUsQXWU5wFGZ7ofYuBA9G9t62ym8lwXLHS-5gyB0MWWL5y0vyaLs65K-rFuo_0wFQ3D_s9xB_3FjwMmgLnYbaRiqDrJ39_8AP_Nd5bQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80163510</pqid></control><display><type>article</type><title>The behavioral pharmacology of NMDA receptor antagonists</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Willetts, Joyce ; Balster, Robert L. ; Leander, J.David</creator><creatorcontrib>Willetts, Joyce ; Balster, Robert L. ; Leander, J.David</creatorcontrib><description>There is considerable interest in the development of NMDA antagonists as potential therapeutic agents in the treatment of convulsant, neurodegenerative and anxiety disorders. Because the clinical use of phencyclidine (PCP) has been precluded by its psychotomimetic effects and abuse potential, there has been concern that other NMDA antagonists including those acting competitively might produce similar untoward effects. However, the studies in animals, reviewed here by Joyce Willetts, Robert Balster and David Leander,
suggest that while there are certain similarities in the behavioral effects of PCP-like and competitive antagonists, there are also differences. These differences have implications for the development of NMDA antagonists with less likelihood for producing PCP-like side-effects.</description><identifier>ISSN: 0165-6147</identifier><identifier>EISSN: 1873-3735</identifier><identifier>DOI: 10.1016/0165-6147(90)90150-7</identifier><identifier>PMID: 2147794</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>1-(cis-2-carboxypiperidine-4-yl)-methyl-l-phosphonic acid ; 2-amino-4 ; 2-amino-5-phosphonovalerate ; 2-arnino-7-phosphonoheptanoate ; 2-cyclohexyl)-7-phosphonoheptanoic acid ; 3-([±]-2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid ; 5-(l ; 6-phosphonomethyl-decahydroisoquinoline-3-carboxylicacid ; [formula omitted] acid ; AF5 ; Animals ; AP7 ; Behavior, Animal - drug effects ; CGP37849 ; CGS19755 ; cis-(±)-4-(2 H-tetrazol-5-yl)methylpiperidine-2-carboxylicacid ; CPP ; formula omitted ; LY233053 ; LY274614 ; NPC12626 ; Phencyclidine - pharmacology ; Receptors, N-Methyl-D-Aspartate - drug effects</subject><ispartof>Trends in pharmacological sciences (Regular ed.), 1990-10, Vol.11 (10), p.423-428</ispartof><rights>1990</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c448t-b5d3a1c86826676ecf1e8d11722804283df6e2b5eaaab4bf1d2e4cff13e0fa13</citedby><cites>FETCH-LOGICAL-c448t-b5d3a1c86826676ecf1e8d11722804283df6e2b5eaaab4bf1d2e4cff13e0fa13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0165-6147(90)90150-7$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2147794$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Willetts, Joyce</creatorcontrib><creatorcontrib>Balster, Robert L.</creatorcontrib><creatorcontrib>Leander, J.David</creatorcontrib><title>The behavioral pharmacology of NMDA receptor antagonists</title><title>Trends in pharmacological sciences (Regular ed.)</title><addtitle>Trends Pharmacol Sci</addtitle><description>There is considerable interest in the development of NMDA antagonists as potential therapeutic agents in the treatment of convulsant, neurodegenerative and anxiety disorders. Because the clinical use of phencyclidine (PCP) has been precluded by its psychotomimetic effects and abuse potential, there has been concern that other NMDA antagonists including those acting competitively might produce similar untoward effects. However, the studies in animals, reviewed here by Joyce Willetts, Robert Balster and David Leander,
suggest that while there are certain similarities in the behavioral effects of PCP-like and competitive antagonists, there are also differences. These differences have implications for the development of NMDA antagonists with less likelihood for producing PCP-like side-effects.</description><subject>1-(cis-2-carboxypiperidine-4-yl)-methyl-l-phosphonic acid</subject><subject>2-amino-4</subject><subject>2-amino-5-phosphonovalerate</subject><subject>2-arnino-7-phosphonoheptanoate</subject><subject>2-cyclohexyl)-7-phosphonoheptanoic acid</subject><subject>3-([±]-2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid</subject><subject>5-(l</subject><subject>6-phosphonomethyl-decahydroisoquinoline-3-carboxylicacid</subject><subject>[formula omitted] acid</subject><subject>AF5</subject><subject>Animals</subject><subject>AP7</subject><subject>Behavior, Animal - drug effects</subject><subject>CGP37849</subject><subject>CGS19755</subject><subject>cis-(±)-4-(2 H-tetrazol-5-yl)methylpiperidine-2-carboxylicacid</subject><subject>CPP</subject><subject>formula omitted</subject><subject>LY233053</subject><subject>LY274614</subject><subject>NPC12626</subject><subject>Phencyclidine - pharmacology</subject><subject>Receptors, N-Methyl-D-Aspartate - drug effects</subject><issn>0165-6147</issn><issn>1873-3735</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtOwzAQRS0EKqXwByBlhWAR8COJnQ1SVZ5SgU33luOMW6MkDnZaqX-PSyuWLEYjzdx7R3MQuiT4jmBS3MfK04Jk_KbEtyUmOU75ERoTwVnKOMuP0fhPcorOQvjCGDNGyQiNaJzxMhsjsVhBUsFKbazzqkn6lfKt0q5xy23iTPLx_jhNPGjoB-cT1Q1q6TobhnCOToxqAlwc-gQtnp8Ws9d0_vnyNpvOU51lYkirvGaKaFEIWhS8AG0IiJoQTqnAGRWsNgXQKgelVJVVhtQUMm0MYYCNImyCrvexvXffawiDbG3Q0DSqA7cOUsQXWU5wFGZ7ofYuBA9G9t62ym8lwXLHS-5gyB0MWWL5y0vyaLs65K-rFuo_0wFQ3D_s9xB_3FjwMmgLnYbaRiqDrJ39_8AP_Nd5bQ</recordid><startdate>19901001</startdate><enddate>19901001</enddate><creator>Willetts, Joyce</creator><creator>Balster, Robert L.</creator><creator>Leander, J.David</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19901001</creationdate><title>The behavioral pharmacology of NMDA receptor antagonists</title><author>Willetts, Joyce ; Balster, Robert L. ; Leander, J.David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c448t-b5d3a1c86826676ecf1e8d11722804283df6e2b5eaaab4bf1d2e4cff13e0fa13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>1-(cis-2-carboxypiperidine-4-yl)-methyl-l-phosphonic acid</topic><topic>2-amino-4</topic><topic>2-amino-5-phosphonovalerate</topic><topic>2-arnino-7-phosphonoheptanoate</topic><topic>2-cyclohexyl)-7-phosphonoheptanoic acid</topic><topic>3-([±]-2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid</topic><topic>5-(l</topic><topic>6-phosphonomethyl-decahydroisoquinoline-3-carboxylicacid</topic><topic>[formula omitted] acid</topic><topic>AF5</topic><topic>Animals</topic><topic>AP7</topic><topic>Behavior, Animal - drug effects</topic><topic>CGP37849</topic><topic>CGS19755</topic><topic>cis-(±)-4-(2 H-tetrazol-5-yl)methylpiperidine-2-carboxylicacid</topic><topic>CPP</topic><topic>formula omitted</topic><topic>LY233053</topic><topic>LY274614</topic><topic>NPC12626</topic><topic>Phencyclidine - pharmacology</topic><topic>Receptors, N-Methyl-D-Aspartate - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Willetts, Joyce</creatorcontrib><creatorcontrib>Balster, Robert L.</creatorcontrib><creatorcontrib>Leander, J.David</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Trends in pharmacological sciences (Regular ed.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Willetts, Joyce</au><au>Balster, Robert L.</au><au>Leander, J.David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The behavioral pharmacology of NMDA receptor antagonists</atitle><jtitle>Trends in pharmacological sciences (Regular ed.)</jtitle><addtitle>Trends Pharmacol Sci</addtitle><date>1990-10-01</date><risdate>1990</risdate><volume>11</volume><issue>10</issue><spage>423</spage><epage>428</epage><pages>423-428</pages><issn>0165-6147</issn><eissn>1873-3735</eissn><abstract>There is considerable interest in the development of NMDA antagonists as potential therapeutic agents in the treatment of convulsant, neurodegenerative and anxiety disorders. Because the clinical use of phencyclidine (PCP) has been precluded by its psychotomimetic effects and abuse potential, there has been concern that other NMDA antagonists including those acting competitively might produce similar untoward effects. However, the studies in animals, reviewed here by Joyce Willetts, Robert Balster and David Leander,
suggest that while there are certain similarities in the behavioral effects of PCP-like and competitive antagonists, there are also differences. These differences have implications for the development of NMDA antagonists with less likelihood for producing PCP-like side-effects.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>2147794</pmid><doi>10.1016/0165-6147(90)90150-7</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0165-6147 |
| ispartof | Trends in pharmacological sciences (Regular ed.), 1990-10, Vol.11 (10), p.423-428 |
| issn | 0165-6147 1873-3735 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80163510 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | 1-(cis-2-carboxypiperidine-4-yl)-methyl-l-phosphonic acid 2-amino-4 2-amino-5-phosphonovalerate 2-arnino-7-phosphonoheptanoate 2-cyclohexyl)-7-phosphonoheptanoic acid 3-([±]-2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid 5-(l 6-phosphonomethyl-decahydroisoquinoline-3-carboxylicacid [formula omitted] acid AF5 Animals AP7 Behavior, Animal - drug effects CGP37849 CGS19755 cis-(±)-4-(2 H-tetrazol-5-yl)methylpiperidine-2-carboxylicacid CPP formula omitted LY233053 LY274614 NPC12626 Phencyclidine - pharmacology Receptors, N-Methyl-D-Aspartate - drug effects |
| title | The behavioral pharmacology of NMDA receptor antagonists |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T00%3A08%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20behavioral%20pharmacology%20of%20NMDA%20receptor%20antagonists&rft.jtitle=Trends%20in%20pharmacological%20sciences%20(Regular%20ed.)&rft.au=Willetts,%20Joyce&rft.date=1990-10-01&rft.volume=11&rft.issue=10&rft.spage=423&rft.epage=428&rft.pages=423-428&rft.issn=0165-6147&rft.eissn=1873-3735&rft_id=info:doi/10.1016/0165-6147(90)90150-7&rft_dat=%3Cproquest_cross%3E80163510%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80163510&rft_id=info:pmid/2147794&rft_els_id=0165614790901507&rfr_iscdi=true |